Dana dhuwit perusahaan Protalix BioTherapeutics, Inc (PLX)

Despite Middle East tensions, the humanitarian status of the Israeli developer Protalix BioTherapeutics (PLX) ensures business stability. The cash balance history confirms financial resilience, where the 0.05 mark records this indicator. Liquidity is supported by patent protection for protein synthesis methods, while the innovative ProCellEx platform enables the creation of affordable therapeutic drugs in plant cells.
Rincian metrik komprehensif lan analitis Protalix BioTherapeutics, Inc. (PLX)

The cash_co indicator measures the total volume of liquid assets, serving as a solvency filter for the issuer during initial screening. This metric is based on reporting data, where the balance between stability and capitalization growth rates determines investment attractiveness. Current cash reserves amounting to 0.05 reflect the financial cushion of Protalix BioTherapeutics (PLX). These resources are critical for navigating stringent FDA oversight during the development of the proprietary ProCellEx platform.